{
    "2021-09-09": [
        [
            {
                "time": "2023-10-15",
                "original_text": "Could This Label Expansion Be a Blockbuster for AbbVie's Shareholders?",
                "features": {
                    "keywords": [
                        "Label Expansion",
                        "Blockbuster",
                        "AbbVie",
                        "Shareholders"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "AbbVie to Present at the Morgan Stanley Healthcare Conference",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Morgan Stanley",
                        "Healthcare Conference"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet",
                "features": {
                    "keywords": [
                        "Clinical Trial",
                        "Epcoritamab",
                        "DuoBody®-CD3xCD20",
                        "Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma",
                        "The Lancet"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}